Neurogene (NGNE) Preferred Stock Liabilities (2013 - 2022)
Neurogene (NGNE) reported Preferred Stock Liabilities of $244.4 million for Q4 2022, up 752.19% on a YoY basis from $28.7 million in Q4 2021, and up 752.19% quarter-over-quarter from $28.7 million in Q4 2021.
Neurogene (NGNE) Preferred Stock Liabilities (2013 - 2022) Analysis & Trends
Neurogene has reported Preferred Stock Liabilities for 3 years, with the latest figure at $244.4 million in Q4 2022.
- For the quarter ending Q4 2022, Preferred Stock Liabilities rose 752.19% year-over-year to $244.4 million; the trailing twelve-month figure through Dec 2022 stood at $244.4 million (up 752.19% YoY), and the FY2022 full-year result was $244.4 million, up 752.19% from the prior year.
- Preferred Stock Liabilities for Q4 2022 stood at $244.4 million, up from $28.7 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $244.4 million in Q4 2022, with the low at $28.7 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 244.37 Mn |
| Dec 31, 2021 | 28.68 Mn |
| Dec 31, 2013 | 73.86 Mn |